Human Microbiome Health

Exploring New Frontiers in Human Microbiome Health

Sara Vidal Sara Vidal in our research lab.

Scientific research is increasingly understanding the unique impact complex and diverse glycans have on immunity and metabolic health.

With this emerging understanding, Gnubiotics has begun applying its innovative glycan technologies to design products which modulate the microbiome safely and effectively by selectively promoting the growth of essential commensal microbes, controlling pathogenic microbes and enhancing the production of metabolites essential for immune protection and regulating inflammatory responses.

Gnubiotics has begun its preclinical research with the goal of enhancing the efficacy of anti-cancer drugs such as ICI’s and act as an anti-inflammatory agent when treating chronic inflammatory diseases such as IBD.


Although immunotherapies have revolutionized the treatment of some cancers, response rates remain suboptimal and differ between patients.

Our candidates aim to capture the therapeutic utility of directly manipulating the microbiome as an approach to control tumoral growth and enhance the efficacy of cancer immunotherapies such as PD-1/PD-L1 inhibitors. Our candidates promote a high microbiome diversity, now recognized as an essential asset in treatment response, and exploit the link between gut microbiota and immune physiology to affect tumor growth and treatment outcome.

Our candidates are currently being tested with the University of Zürich (Switzerland) in mice models of CRC and melanoma tumors.


Antimicrobial resistance

CRE, ESBL, VRE and MDR P. aeruginosa are all recognized as urgent and serious antibiotic resistance threats by the US Centers for Disease Control (CDC).

Through their ability to fortify the microbiome and selectively promote commensal bacteria over pathogens, our candidates aim to reduce colonization by these pathogenic bacteria and support the maintenance of the intestinal barrier, limiting subsequent systemic infection.

Our candidates are currently being tested in collaboration with NIAID to demonstrate safety and efficacy.

Inflammatory & metabolic diseases

Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the intestinal tract. Worldwide, over 2.5 million people of European ancestry are affected.

It becomes apparent that an imbalance of the intestinal flora leads to an activation of the immune system that can cause the disease. Our candidates aim to restore the microbiome to a state that supports the epithelial barrier and exerts immunoregulatory function.

Our candidates are currently being tested in collaboration with the University of Zürich (Switzerland) in mice models to demonstrate that they can act as anti-inflammatory agents.

Products & Pipeline Candidates

Our Pipeline:
Candidates & Indications
Human - Supportive Care

AMR infection

CRE, ESBL, VRE, MDR P. aeruginosa

Inflammatory & Metabolic



Colorectal cancer



Scientific publications & References

Our product candidates are supported by scientific publications involving members of the Gnubiotics team and by third-party evidence.

For more information

Fill in the form and our team will get back to you.